Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers.

Next Previous
Trial Profile

Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Sponsors IRIS

Most Recent Events

  • 01 Mar 2012 Status changed from recruiting to completed as reported by ISRCTN.
  • 12 May 2011 Planned end date changed from 30 Sep 2011 to 29 Feb 2012 as reported by ISRCTN.
  • 03 Dec 2010 Planned end date (30 Sep 2011) added as reported by ISRCTN: Current Controlled Trials record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top